PriceTargets.com logo

Cognition Therapeutics - CGTX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $3.33
  • Forecasted Upside: 89.39%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 1 Strong Buy Ratings
$1.76 As of 12/4/2025 05:00 PM ET
▼ -0.04 (-2.22%)

This chart shows the closing price for CGTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cognition Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CGTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CGTX

Analyst Price Target is $3.33
▲ +89.39% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Cognition Therapeutics in the last 3 months. The average price target is $3.33, with a high forecast of $4.00 and a low forecast of $3.00. The average price target represents a 89.39% upside from the last price of $1.76.

This chart shows the closing price for CGTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 investment analysts is to moderate buy stock in Cognition Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/4/2025HC WainwrightReiterated RatingBuy ➝ Buy$3.00
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/24/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/21/2025B. RileyReiterated RatingBuy ➝ Buy$2.00 ➝ $3.00
11/19/2025HC WainwrightReiterated RatingBuy ➝ Buy$3.00
11/18/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
8/8/2025Chardan CapitalReiterated RatingBuy ➝ Buy$4.00
6/26/2025HC WainwrightReiterated RatingBuy ➝ Buy$3.00
5/27/2025HC WainwrightLower TargetBuy ➝ Buy$5.00 ➝ $3.00
5/8/2025Chardan CapitalLower TargetBuy ➝ Buy$8.00 ➝ $4.00
3/24/2025HC WainwrightLower TargetBuy ➝ Buy$6.00 ➝ $5.00
3/21/2025Chardan CapitalLower TargetBuy ➝ Buy$11.00 ➝ $8.00
2/26/2025Chardan CapitalReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
1/27/2025Brookline Capital ManagementUpgradeStrong-Buy
12/19/2024B. RileyUpgradeNeutral ➝ Buy$1.00 ➝ $1.50
12/19/2024HC WainwrightBoost TargetBuy ➝ Buy$5.00 ➝ $6.00
12/19/2024Chardan CapitalReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
11/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
11/15/2024Chardan CapitalReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
11/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
10/31/2024Chardan CapitalReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
8/12/2024HC WainwrightLower TargetBuy ➝ Buy$7.00 ➝ $5.00
8/6/2024B. RileyReiterated RatingBuy ➝ Neutral$5.00 ➝ $1.00
8/1/2024HC WainwrightLower TargetBuy ➝ Buy$10.00 ➝ $7.00
7/30/2024Cantor FitzgeraldDowngradeOverweight ➝ Neutral
7/2/2024Rodman & RenshawReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
6/6/2024Chardan CapitalInitiated CoverageBuy$11.00
5/29/2024HC WainwrightInitiated CoverageBuy$10.00
3/28/2024B. RileyReiterated RatingBuy ➝ Buy$5.00
3/27/2024OppenheimerReiterated RatingOutperform ➝ Outperform$9.00
8/14/2023LADENBURG THALM/SH SHLower TargetBuy ➝ Buy$10.00 ➝ $6.00
11/15/2022OppenheimerLower Target$18.00 ➝ $9.00
9/29/2022Cantor FitzgeraldReiterated RatingOverweight
4/22/2022LADENBURG THALM/SH SHInitiated CoverageBuy$10.00
1/24/2022B. RileyLower Target$27.00 ➝ $20.00
11/30/2021B. RileyReiterated RatingBuy
11/3/2021OppenheimerInitiated CoverageOutperform$22.00
11/3/2021B. RileyInitiated CoverageBuy$27.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 4 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 5 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 5 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Cognition Therapeutics logo
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.
Read More

Today's Range

Now: $1.76
Low: $1.73
High: $1.81

50 Day Range

MA: $1.64
Low: $1.33
High: $1.95

52 Week Range

Now: $1.76
Low: $0.22
High: $3.83

Volume

937,850 shs

Average Volume

976,184 shs

Market Capitalization

$155.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Cognition Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Cognition Therapeutics in the last year: B. Riley, Brookline Capital Management, Chardan Capital, HC Wainwright, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for CGTX.

What is the current price target for Cognition Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Cognition Therapeutics in the last year. Their average twelve-month price target is $3.33, suggesting a possible upside of 89.9%. Chardan Capital has the highest price target set, predicting CGTX will reach $4.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $3.00 for Cognition Therapeutics in the next year.
View the latest price targets for CGTX.

What is the current consensus analyst rating for Cognition Therapeutics?

Cognition Therapeutics currently has 1 sell rating, 3 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CGTX.

What other companies compete with Cognition Therapeutics?

Other companies that are similar to Cognition Therapeutics include Fulcrum Therapeutics, Inventiva, Jade Biosciences, Monopar Therapeutics and Invivyd. Learn More about companies similar to Cognition Therapeutics.

How do I contact Cognition Therapeutics' investor relations team?

The company's listed phone number is 412-481-2210 and its investor relations email address is [email protected]. The official website for Cognition Therapeutics is www.cogrx.com. Learn More about contacing Cognition Therapeutics investor relations.